[ad_1]
The coronavirus vaccine developed jointly by Oxford and AstraZeneca was announced to be 70 percent effective in protecting against the virus.
According to the Reuters news, AstraZeneca announced that the new coronavirus vaccine developed with the University of Oxford showed an average efficiency of 70 percent in protecting against the virus in two segments of the study.
Britain’s Health Minister Matt Hancock commented on the Oxford vaccine as big news, the data showed.
“We have 100 million doses. Most of the distribution will be in the new year,” Minister Hancock said.
“GENERATED A STRONG IMMUNITY REACTION IN THE ELDERLY”
The candidate vaccine developed in conjunction with AstraZeneca, the pharmaceutical company at the University of Oxford in England, against the new type of coronavirus (Covid-19) was reported to have created a strong immune response in the elderly in stage 2 trials.
“DEVELOPED STRONG IMMUNITY IN THOSE AT RISK OF DEATH OR SERIOUS ILLNESS”
In the article published in the Lancet medical journal on the Covid-19 vaccine candidate developed by AstraZeneca in collaboration with the University of Oxford, the results of the second phase trials in which two doses of vaccine or one dose were administered were shared. placebo to approximately 560 healthy adult volunteers. In trials of the first and second phase of the vaccine, it was claimed that it developed strong immunity in groups at risk of death or serious illness due to Covid-19.
NO SPECIFIED SIDE EFFECTS
In the second-stage trials, the vaccine was observed to show similar antibody and T-cell responses in all volunteers in 3 different age groups, 18-55, 56-69, 70 and over, and the volunteers reported no effect secondary.
Oxford Vaccine Group researcher Dr Maheshi Ramasamy stated that they were pleased to see that the vaccine produced similar immune responses not only in the elderly but also in the young.
VACCINE TRIALS DISCONTINUED IN US
In early September, trials of the second phase vaccine conducted by the company AstraZeneca with the University of Oxford against the virus were suspended in the US due to a neurological problem in one of the subjects, but it was announced that AstraZeneca would continue his studies after it was decided that the problem was not caused by the Covid-19 vaccine.
